Navigation Links
Diving deeper into the gene pool
Date:9/27/2010

About ten years ago, the discovery of microRNAs ― tiny cellular molecules that regulate our genetic code ― unlocked a world of scientific possibilities, including a deeper understanding of human disease. One new analytical technology is "deep sequencing," which gives scientists the ability to discover invaluable information about human diseases at a genetic level. Now, Tel Aviv University researchers have developed the cutting-edge technology to better analyze these results.

The software, called miRNAkey, was developed by Roy Ronen as part of a team of researchers headed by Dr. Noam Shomron of the Sackler Faculty of Medicine. Dr. Shomron says that miRNAkey searches for microRNA patterns in both healthy and diseased tissues, improving scientists' understanding of the data collected from deep sequencing technology.

The software package was recently described in the journal Bioinformatics.

Making sense of microRNA patterns

Deep sequencing is used to determine the ultimate sequence and expression of cellular DNA or RNA. Once these molecules are extracted, scientists must be able to read the valuable information that the data supplies. Among these are the entire human genome sequence, the expression of the genes from the genome, and the molecules, such as microRNA, which regulate genetic expression. In short, it allows biologists to see further into human genetics and determine where and when genetic malfunctions might occur.

Until now there were very few unified codes that could interpret what information the microRNA held, and none that could run on a local computer or explain ambiguous microRNA behaviors. The solution is the miRNAkey program, says Dr. Shomron. It is designed to identify the relevant microRNA molecule, determine its level, then generate statistically valuable information from it.

"Such identification of microRNAs allows us to manipulate them," Dr. Shomron explains. One example of this potential manipulation is the alteration of malignant tumors. In one study Dr. Shomron and his team of researchers were able to identify the relevant microRNA molecules in an aggressive malignant form of cancer. They then inserted the healthy, non-aggressive form of these microRNAs into the diseased, aggressive molecule. In an animal model, this resulted in a significant slowing of tumor growth.

Results right to the computer screen

With his software, says Dr. Shomron, data obtained from deep sequencing can be quickly and correctly analyzed, allowing scientists to take a deeper look into disease behavior and potentially build specialized treatments with this knowledge. It may also encourage the creation of "smart drugs" which target individual damaged cells.

With a user-friendly interface, miRNAkey can be used on any local computer alongside the proper deep sequencing technology. Unique features such as data statistics and detailed reports provide valuable information about extracted microRNA, notes Dr. Shomron.


'/>"/>

Contact: George Hunka
ghunka@aftau.org
212-742-9070
American Friends of Tel Aviv University
Source:Eurekalert

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... April 25, 2017 , ... As pharmaceutical companies are held ... with process innovation in drug formulation and manufacturing. CoreRx offers its clients ... equipment in support of their development and manufacturing goals. , The company ...
(Date:4/25/2017)... ... April 25, 2017 , ... Back Pain Centers ... back pain with a reputable physician in their area, announces the launch of a ... information for patients who are looking for reputable physicians to help them with back ...
(Date:4/25/2017)... ... April 25, 2017 , ... Saad B. Chaudhary, MD is committed to providing the highest ... chronic problems, I focus on preventative care with all my patients to alleviate possible future ... always feel free to contact my office and my trained staff will assist you in ...
(Date:4/25/2017)... ... April 25, 2017 , ... Emergency Physician and Distinguished Professor of Emergency ... Series, Outliers in Writing, set to publish in summer 2017. , Dr. Bobrow, ... University of Arizona College of Medicine. He also serves as Medical Director for the ...
(Date:4/25/2017)... ... ... Vetoquinol USA® , a world-class developer of veterinarian-approved ... EQUISTRO line, at this week’s Rolex Kentucky Three-Day Event in Lexington. Flexadin UCII ... The scientifically-developed Flexadin UCII supports the body’s normal repair of cartilage and joints. ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017  RXi Pharmaceuticals Corporation (NASDAQ: ... that address significant unmet medical needs, today announced ... Company,s consumer product development program, based on its ... for Investigative Dermatology (SID) 76 th Annual ... promote the sciences relevant to skin health and ...
(Date:4/20/2017)... 2017  AbbVie (NYSE: ABBV), a global biopharmaceutical ... chronic hepatitis C virus (HCV) infected patients with ... compensated cirrhosis (Child-Pugh A) achieved sustained virologic response ... its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These ... 12 weeks of G/P treatment without ribavirin. Patients ...
(Date:4/20/2017)... Research and Markets has announced the addition of ... By Service (Manufacturing, Research), By Country, (Brazil, Mexico, Colombia, Argentina, ... to their offering. ... The Latin American pharmaceutical contract manufacturing services market is anticipated ... drug registration cost in Latin American countries and continuous economic ...
Breaking Medicine Technology: